Cargando…
Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective
Diagnosing and managing metabolic dysfunction-associated steatotic liver disease (MASLD) remains a major challenge in primary care due to lack of agreement on diagnostic tools, difficulty in identifying symptoms and determining their cause, absence of approved pharmacological treatments, and limited...
Autores principales: | Eskridge, Wayne, Cryer, Donna R., Schattenberg, Jörn M., Gastaldelli, Amalia, Malhi, Harmeet, Allen, Alina M., Noureddin, Mazen, Sanyal, Arun J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10573476/ https://www.ncbi.nlm.nih.gov/pubmed/37834859 http://dx.doi.org/10.3390/jcm12196216 |
Ejemplares similares
-
Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
por: Staufer, Katharina, et al.
Publicado: (2023) -
Noninvasive Testing Using Magnetic Resonance Imaging Techniques as Outcomes in Nonalcoholic Steatohepatitis Clinical Trials: How Full Is the Glass?
por: Noureddin, Nabil, et al.
Publicado: (2020) -
From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials
por: Yeh, Ming-Lun, et al.
Publicado: (2023) -
Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor
por: Platek, Anna E., et al.
Publicado: (2023) -
Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors
por: Takahashi, Yoshihisa, et al.
Publicado: (2023)